Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage ...

The retail business saw strong momentum riding on quick commerce. The 22% and 23% topline growth in fashion and grocery was a ...

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC ...

Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

The cordless power tool market is now fundamentally driven by battery innovation, according to industry analysts. As Milwaukee Tool continues to roll out increasingly advanced battery platforms, the ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

The post FBI investigating “suspicious” hunting stand near Air Force One landing zone appeared first on Salon.com. The ...

For most skin types, 5 to 10% glycolic or lactic acids or 1 to 2% salicylic acid is a safe starting point. Sensitive skin may ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...